NCT02509117 - First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Healthy Subjects

Interventions

DRUG

PF-06751979 single ascending dose

PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.

DRUG

Placebo single dose

Matched Placebo solution/suspension administered as single dose.

DRUG

PF-06751979 multiple ascending dose

PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.

DRUG

Placebo multiple dose

Matched Placebo (solution/suspension)administered daily for 14 consecutive days.

DRUG

PF-06751979 multiple dose

PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.

DRUG

PF-06751979 multiple dose

Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.

Trial Locations (2)

91206

California Clinical Trials Medical Group, Inc, Glendale

Glendale Adventist Medical Center, Glendale